Cargando…

Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease

Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristi...

Descripción completa

Detalles Bibliográficos
Autores principales: Troshev, Dmitry, Voronkov, Dmitry, Pavlova, Anastasia, Abaimov, Denis, Latanov, Alexander, Fedorova, Tatiana, Berezhnoy, Daniil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962442/
https://www.ncbi.nlm.nih.gov/pubmed/35203675
http://dx.doi.org/10.3390/biomedicines10020466
_version_ 1784677805712211968
author Troshev, Dmitry
Voronkov, Dmitry
Pavlova, Anastasia
Abaimov, Denis
Latanov, Alexander
Fedorova, Tatiana
Berezhnoy, Daniil
author_facet Troshev, Dmitry
Voronkov, Dmitry
Pavlova, Anastasia
Abaimov, Denis
Latanov, Alexander
Fedorova, Tatiana
Berezhnoy, Daniil
author_sort Troshev, Dmitry
collection PubMed
description Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristics of the disease. One of such models, in which neuropathology is induced by chronic injections of low doses of mitochondrial toxin rotenone, is well established in rats. However, data on this model adapted to mice remain controversial. We have designed the study to describe the timecourse of motor and non-motor symptoms during chronic subcutaneous administration of rotenone (4 mg/kg daily for 35 days) in C57BL/6 mice. We characterize the underlying neuropathological processes (dopaminergic neuron degeneration, regional brain metabolism, monoamine neurotransmitter and lipid peroxidation changes) at different timepoints: 1 day, 2 weeks and 5 weeks of daily rotenone exposure. Based on the behavioral data, we can describe three stages of pathology: cognitive changes from week 2 of rotenone exposure, subtle motor changes in week 3–4 and motor dysfunction starting roughly from week 4. Neuropathological changes in this model include a general decrease in COX activity in different areas of the brain (acute effect of rotenone) and a more specific decrease in midbrain (chronic effect), followed by significant neurodegeneration in SNpc but not VTA by the 5th week of rotenone exposure. However, we were unable to find changes in the level of monoamine neurotransmitters neither in the striatum nor in the cortex, nor in the level of lipid peroxidation in the brainstem. Thus, the gradual progression of pathology in this model is linked with metabolic changes, rather than with oxidative stress or tonic neurotransmitter release levels. Overall, this study supports the idea that a low-dose rotenone mouse model can also reproduce different stages of PD as well as rats.
format Online
Article
Text
id pubmed-8962442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89624422022-03-30 Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease Troshev, Dmitry Voronkov, Dmitry Pavlova, Anastasia Abaimov, Denis Latanov, Alexander Fedorova, Tatiana Berezhnoy, Daniil Biomedicines Article Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristics of the disease. One of such models, in which neuropathology is induced by chronic injections of low doses of mitochondrial toxin rotenone, is well established in rats. However, data on this model adapted to mice remain controversial. We have designed the study to describe the timecourse of motor and non-motor symptoms during chronic subcutaneous administration of rotenone (4 mg/kg daily for 35 days) in C57BL/6 mice. We characterize the underlying neuropathological processes (dopaminergic neuron degeneration, regional brain metabolism, monoamine neurotransmitter and lipid peroxidation changes) at different timepoints: 1 day, 2 weeks and 5 weeks of daily rotenone exposure. Based on the behavioral data, we can describe three stages of pathology: cognitive changes from week 2 of rotenone exposure, subtle motor changes in week 3–4 and motor dysfunction starting roughly from week 4. Neuropathological changes in this model include a general decrease in COX activity in different areas of the brain (acute effect of rotenone) and a more specific decrease in midbrain (chronic effect), followed by significant neurodegeneration in SNpc but not VTA by the 5th week of rotenone exposure. However, we were unable to find changes in the level of monoamine neurotransmitters neither in the striatum nor in the cortex, nor in the level of lipid peroxidation in the brainstem. Thus, the gradual progression of pathology in this model is linked with metabolic changes, rather than with oxidative stress or tonic neurotransmitter release levels. Overall, this study supports the idea that a low-dose rotenone mouse model can also reproduce different stages of PD as well as rats. MDPI 2022-02-16 /pmc/articles/PMC8962442/ /pubmed/35203675 http://dx.doi.org/10.3390/biomedicines10020466 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Troshev, Dmitry
Voronkov, Dmitry
Pavlova, Anastasia
Abaimov, Denis
Latanov, Alexander
Fedorova, Tatiana
Berezhnoy, Daniil
Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease
title Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease
title_full Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease
title_fullStr Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease
title_full_unstemmed Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease
title_short Time Course of Neurobehavioral Disruptions and Regional Brain Metabolism Changes in the Rotenone Mice Model of Parkinson’s Disease
title_sort time course of neurobehavioral disruptions and regional brain metabolism changes in the rotenone mice model of parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962442/
https://www.ncbi.nlm.nih.gov/pubmed/35203675
http://dx.doi.org/10.3390/biomedicines10020466
work_keys_str_mv AT troshevdmitry timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease
AT voronkovdmitry timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease
AT pavlovaanastasia timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease
AT abaimovdenis timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease
AT latanovalexander timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease
AT fedorovatatiana timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease
AT berezhnoydaniil timecourseofneurobehavioraldisruptionsandregionalbrainmetabolismchangesintherotenonemicemodelofparkinsonsdisease